Dyne Therapeutics (DYN)Perceptive Advisors LLC reduced its stake -1.98M shares

2.69M

Shares reported · -1.98M vs prior quarter

0.90%

Disclosed portfolio weight

$59.7M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 16, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
2. Jun 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 22, 2026, the Board of Directors (the “Board”) of Dyne Therapeutics, Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Barry E. Greene as a Class I director to serve on the Board until the Company’s 2027 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or…”
3. Jul 21, 2026Company filing · Form 8-K · Material agreement, Other newsSigned an important agreement, and reported other company news
4. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Oct 2, 2026Insider · First insider buy since Jul 2025Director purchased ~$40K of DYN shares in the open market

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Dyne Therapeutics

For Dyne Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 6 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DYN page.

How this filing works

• SEC Form 13F

Other disclosures at Dyne Therapeutics

• SEC Form 4Oct 7, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 13, 2026

Everything OQRO holds on this company is on its DYN page.